.After increasing $170 thousand back in February, metabolic disease-focused BioAge Labs has submitted to debut on everyone market.The Eli Lilly-partnered biotech want to list on the Nasdaq under the symbolic representation “BIOA,” according to files filed with the Stocks and also Substitution Percentage. The company has actually certainly not openly discussed an anticipated monetary amount for the offering.The clinical-stage company touts lead candidate azelaprag, a by mouth supplied small particle slated to enter phase 2 testing in combination along with semaglutide– marketed by Novo Nordisk under trademark name Wegovy for fat burning– in the initial fifty percent of following year. Semaglutide is actually also sold as Ozempic and also Rybelsus by Novo for diabetic issues.
Apelin receptor agonist azelaprag is actually designed to combine effectively with GLP-1 medicines, improving weight loss while keeping muscular tissue mass. The investigational drug was found to become well-tolerated one of 265 individuals all over 8 phase 1 tests, depending on to BioAge.Earlier, BioAge amassed the assistance of Lilly to manage a test combining azelaprag along with the Large Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is industried for diabetes as Mounjaro and also Zepbound for effective weight loss. The companions are actually currently conducting a stage 2 trial of azelaprag and tirzepatide, with topline end results anticipated in the third fourth of 2025.The biotech is likewise preparing a blood insulin sensitivity proof-of-concept trial examining azelaprag as a monotherapy in the very first half of upcoming year to sustain prospective indicator expansion.
Moreover, the firm prepares to ask the FDA for approval in the 2nd one-half of 2025 to launch individual screening for an NLRP3 prevention targeting metabolic illness and also neuroinflammation.BioAge’s foreseed move to the general public market observes a mild uptick in organized biotech IPOs from Bicara Rehabs as well as Zenas Biopharma. Zooming out, the recent IPO landscape is actually a “combined picture,” with top quality business still debuting on everyone markets, only in minimized numbers, according to PitchBook.